trial
as of 2026-07-01Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
NCTId NCT00946348
at a glance
Phase 1 · Completed
Enrollment 12 (actual)
Sponsored by Dartmouth-Hitchcock Medical Center
Primary completion 2012-10
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-12
Primary completion
2012-10
Eligibility
ALL · 18 Years · 50 Years
Interventions & indications
Sponsors
Dartmouth-Hitchcock Medical CenterLead Sponsor
National Institute on Drug Abuse (NIDA)Collaborator
Indiana UniversityCollaborator
Columbia UniversityCollaborator
University of VermontCollaborator
University of Massachusetts, WorcesterCollaborator
Investigators
1
Alan I. Green, MDPrincipal Investigator
Sites
1 total
Lebanon, United States
Facts & assertions
4 sourced
Enrollment
12
Phase
PHASE1
Primary Completion Date
2012-10
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
collaborator
indication
investigator
person